Evercore ISI Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,175.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lowered by equities researchers at Evercore ISI from $1,250.00 to $1,175.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Evercore ISI’s price objective would indicate a potential upside of 25.10% from the company’s current price.

Other research analysts have also recently issued research reports about the stock. Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a “buy” rating for the company in a research note on Wednesday, October 16th. Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. TD Cowen raised their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, Barclays lowered their price objective on shares of Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $1,101.00.

Regeneron Pharmaceuticals Stock Performance

REGN traded down $2.12 during trading on Thursday, reaching $939.27. 82,991 shares of the company’s stock were exchanged, compared to its average volume of 502,358. The business has a 50 day moving average price of $1,098.29 and a 200 day moving average price of $1,040.67. The company has a market capitalization of $103.49 billion, a P/E ratio of 27.78, a PEG ratio of 3.40 and a beta of 0.12. Regeneron Pharmaceuticals has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the prior year, the business posted $8.79 earnings per share. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals will post 37.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $26,000. Sachetta LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the period. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $28,000. Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. Finally, Family Firm Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $33,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.